Australia - English - Department of Health (Therapeutic Goods Administration)

emergent sales and marketing australia pty ltd - vaccinia virus, quantity: 100000000 pfu/ml - injection, powder for - excipient ingredients: sodium chloride; albumin; neomycin sulfate; mannitol; hepes; polymyxin b sulfate - acam2000 is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection in an officially declared outbreak.

Canada - English - Health Canada

dolisos laboratoires s.a. - vaccinium myrtillus - drops - 1dh - vaccinium myrtillus 1dh - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - vaccinium myrtillus - globules - 1x - vaccinium myrtillus 1x - homeopathic products

United States - English - NLM (National Library of Medicine)

washington homeopathic products - vaccinium - to relieve the symptoms of diarrhea. indications: vaccinium   diarrhea if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - vaccinium myrtillus - to relieve the symptoms of diarrhea. indications: vaccinium diarrhea if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

United States - English - NLM (National Library of Medicine)

emergent product development gaithersburg inc. - vaccinia virus strain new york city board of health live antigen (unii: 4sv59689sk) (vaccinia virus strain new york city board of health live antigen - unii:4sv59689sk) - acam2000® is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. there are very few absolute contraindications to this vaccine for those who are at high risk for smallpox. the risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection. see warnings and precautions (5) for persons who are at higher risk of experiencing serious vaccination complications. severe immune deficiency severe localized or systemic infection with vaccinia (progressive vaccinia) may occur in persons with weakened immune systems. individuals with severe immunodeficiency who are not expected to benefit from the vaccine should not receive acam2000. these individuals may include individuals who are undergoing bone marrow transplantation or individuals with primary or acquired immunodeficiency who require isolation. acam2000 has not been studied in pregnant women. live vaccini

United States - English - NLM (National Library of Medicine)

emergent biosolutions canada inc. - human vaccinia virus immune globulin (unii: 7ub4j759td) (human vaccinia virus immune globulin - unii:7ub4j759td) - human vaccinia virus immune globulin 1 [iu] in 1 ml - vigiv (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: vigiv is not considered to be effective in the treatment of postvaccinial encephalitis. vigiv is contraindicated in: risk summary there are no data on the use of vigiv in pregnant women to inform on drug-associated risk. animal reproduction studies have not been conducted with vigiv. risk summary there are no data to assess the presence or absence of vigiv in human milk, the effects on the breastfed child or the effects on milk production/excretion. safety and effectiveness in the pediatric population (<16 yrs of age) has not been established for vigiv. safety and effectiveness in the geriatric population (>65 yrs of age) has not been established for vigiv.

European Union - English - EMA (European Medicines Agency)

bavarian nordic a/s - modified vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - other viral vaccines, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).the use of this vaccine should be in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - vaccinia virus strain new york city board of health live antigen (unii: 4sv59689sk) (vaccinia virus strain new york city board of health live antigen - unii:4sv59689sk) - vaccinia virus strain new york city board of health live antigen 30 [hp_c] in 1 ml - for temporary relief of symptoms of smallpox, such as flu, discomfort, headache, fatigue and vomiting.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms of smallpox, such as flu, discomfort, headache, fatigue and vomiting.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

bavarian nordic a/s - vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen (unii: tu8j357395) (vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen - unii:tu8j357395) - jynneos is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available human data on jynneos administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. the effect of jynneos on embryo-fetal and post-natal development was evaluated in four developmental toxicity studies conducted in female rats and rabbits. in two studies, rats were administered a single human dose of jynneos (0.5 ml) once prior to mating and on one or two occasions during gestation. in the third study, rats were administered a single human dose of jynneos (0.5 ml) on two occasions during gestation. in the fourth study, rabbits were ad